Epilepsy
RAPPRapport Therapeutics IncCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for RAP-219 Long-Acting Injectable (RAP-219) (TARPγ8 NAM) in Epilepsy. The expected timing is based on the latest available company guidance and may change.
05/07/26:- RAP-219 long-acting injectable IND-enabling ongoing; initial Phase 1 pharmacokinetic data expected in 2027. 08/05/26:- LAI IND-enabling continues; initial Ph1 PK data expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.